Omada Health, Inc. (OMDA)
AI stock analysis · Health Information Services · Last analyzed Aug 20, 2026
Omada Health is a digital chronic disease management platform delivering exceptional top-line momentum — 43.1% revenue growth YoY — as it scales its diabetes prevention and hypertension programs across employer and health plan channels. Analyst sentiment is firmly bullish with 10 Buy ratings and zero sells, and the company has beaten earnings expectations in each of its first 4 public quarters, demonstrating early but consistent execution. The primary risk is a rich and expanding forward valuation (44x forward P/E) that leaves little room for execution missteps or a slowdown in member enrollment growth.
- Next quarterly earnings report — continued 43%+ revenue growth and a 5th consecutive EPS beat would materially strengthen the bull case and likely drive consensus target upgrades.
- Expansion of health plan and employer contracts — any announced large-scale payor partnerships or enterprise wins could accelerate the path to profitability and re-rate the stock.
- Potential inclusion in healthcare indices or institutional coverage initiations — with 12 analysts already covering the name, additional Buy initiations or index inclusion could drive incremental demand for shares.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →